Symeres
Private Company
Funding information not available
Overview
Symeres is a rapidly growing, integrated CRO/CDMO partner specializing in small molecule and drug delivery services from discovery to IND. With over 600 scientists across nine sites in Europe and North America, it offers a unified, transparent approach designed to reduce handoff delays and accelerate client programs. The company is trusted by a global clientele, from biotechs to large pharma, and differentiates itself through deep expertise, operational nimbleness, and a strong focus on data security and client communication.
Technology Platform
Integrated CRO/CDMO service platform combining medicinal/synthetic chemistry, biology, ADME-tox, CMC, and drug delivery (lipid/polymer) expertise under a single program lead from discovery to IND.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Symeres competes in a fragmented but crowded market with large global CROs (e.g., LabCorp, IQVIA, Charles River), integrated CDMOs (e.g., Lonza, Catalent), and specialized chemistry service providers. Its differentiation lies in its focused integration of discovery and early development services for small molecules and drug delivery, offering a streamlined alternative to using multiple vendors.